Jones Financial Companies
SRPT icon

Jones Financial Companies’s Sarepta Therapeutics SRPT Stock Holding History

Jones Financial Companies’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9K Sell
645
-415
-39% -$7.85K ﹤0.01% 3759
2026
Q1 		$21.2K Buy
1,060
+212
+25% +$4.1K ﹤0.01% 3273
2025
Q4 		$18.2K Buy
848
+302
+55% +$6.37K ﹤0.01% 2972
2025
Q3 		$10K Sell
546
-2,165
-80% -$38.6K ﹤0.01% 3080
2025
Q2 		$46.4K Buy
2,711
+2,113
+353% +$90.1K ﹤0.01% 2249
2025
Q1 		$42.1K Buy
598
+70
+13% +$7.37K ﹤0.01% 2129
2024
Q4 		$64.2K Buy
528
+387
+274% +$47.4K ﹤0.01% 1781
2024
Q3 		$17.6K Buy
+141
New +$19.5K ﹤0.01% 2002
2021
Q2 		– Sell
-15
Closed -$1K – 779
2021
Q1 		$1K Buy
+15
New +$1.38K ﹤0.01% 772

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jones Financial Companies's SRPT Position: Q2 2026 in Review

Jones Financial Companies reduced its Sarepta Therapeutics (SRPT) stake by 39% in Q2 2026, selling an estimated $7.85K and leaving 645 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3759.

Jones Financial Companies first reported a position in SRPT in Q1 2021 and has held it in 9 quarters since. The position peaked at $64.2K in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Jones Financial Companies held 645 shares of Sarepta Therapeutics worth $10.9K as of Q2 2026.
  • Jones Financial Companies sold 415 Sarepta Therapeutics shares in Q2 2026, an estimated $7.85K.
  • Sarepta Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3759 holding.
  • Jones Financial Companies first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • Jones Financial Companies's Sarepta Therapeutics position peaked at $64.2K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.